Comparing Decentralized Learning Methods for Health Data Models to Nondecentralized Alternatives: Protocol for a Systematic Review.

BACKGROUND: Considering the soaring health-related costs directed toward a growing, aging, and comorbid population, the health sector needs effective data-driven interventions while managing rising care costs. While health interventions using data mining have become more robust and adopted, they often demand high-quality big data. However, growing privacy concerns have hindered large-scale data sharing. In parallel, recently introduced legal instruments require complex implementations, especially when it comes to biomedical data. New privacy-preserving technologies, such as decentralized learning, make it possible to create health models without mobilizing data sets by using distributed computation principles. Several multinational partnerships, including a recent agreement between the United States and the European Union, are adopting these techniques for next-generation data science. While these approaches are promising, there is no clear and robust evidence synthesis of health care applications. OBJECTIVE: The main aim is to compare the performance among health data models (eg, automated diagnosis and mortality prediction) developed using decentralized learning approaches (eg, federated and blockchain) to those using centralized or local methods. Secondary aims are comparing the privacy compromise and resource use among model architectures. METHODS: We will conduct a systematic review using the first-ever registered research protocol for this topic following a robust search methodology, including several biomedical and computational databases. This work will compare health data models differing in development architecture, grouping them according to their clinical applications. For reporting purposes, a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 flow diagram will be presented. CHARMS (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies)-based forms will be used for data extraction and to assess the risk of bias, alongside PROBAST (Prediction Model Risk of Bias Assessment Tool). All effect measures in the original studies will be reported. RESULTS: The queries and data extractions are expected to start on February 28, 2023, and end by July 31, 2023. The research protocol was registered with PROSPERO, under the number 393126, on February 3, 2023. With this protocol, we detail how we will conduct the systematic review. With that study, we aim to summarize the progress and findings from state-of-the-art decentralized learning models in health care in comparison to their local and centralized counterparts. Results are expected to clarify the consensuses and heterogeneities reported and help guide the research and development of new robust and sustainable applications to address the health data privacy problem, with applicability in real-world settings. CONCLUSIONS: We expect to clearly present the status quo of these privacy-preserving technologies in health care. With this robust synthesis of the currently available scientific evidence, the review will inform health technology assessment and evidence-based decisions, from health professionals, data scientists, and policy makers alike. Importantly, it should also guide the development and application of new tools in service of patients' privacy and future research. TRIAL REGISTRATION: PROSPERO 393126; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=393126. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/45823.

Hyperkalemia as a limiting factor of neurohormonal blockade/modulation in everyday clinical practice.

INTRODUCTION AND OBJECTIVES: Neurohormonal blockade (NB)/modulation is the combination of two renin-angiotensin-aldosterone system inhibitors (RAASi) with a beta blocker. It is the core therapy for heart failure with reduced ejection fraction (HFrEF). While improving long term prognosis, it also induces hyperkalemia (serum K+ >5.0 mEq/L) due to RAASi effects. This may cause lethal arrhythmias and increase mortality in the short term. Thus, hyperkalemia frequently leads to withholding or reducing the intensity of neurohormonal blockade/modulation, which is associated with worsening long term prognosis. We assessed the relevance of hyperkalemia as a limiting factor of neurohormonal blockade/modulation in real life clinical conditions. METHODS: We reviewed the medical records of HFrEF patients attending a HF clinic at a tertiary Portuguese hospital during 2018 (n=240). The number of patients not tolerating maximal neurohormonal blockade/modulation due to hyperkalemia was determined. The incidence and characteristics of hyperkalemia episodes were also assessed. RESULTS: Only six patients (3%) achieved maximal doses of neurohormonal blockade/modulation. Hyperkalemia was the limiting factor in 48 (20%) patients. A total of 185 hyperkalemia episodes occurred in 100 (42%) patients. Forty-five (24%) episodes were moderate or severe (serum K+ >5.5 mEq/L). In these HFrEF patients, the co-existence of hypertension, diabetes or renal failure was associated with the occurrence of hyperkalemia. CONCLUSIONS: In daily clinical practice, hyperkalemia is frequent and limits neurohormonal blockade/modulation by leading to the withholding or reducing of the intensity of RAAS inhibition. Considering the negative prognostic impact associated with sub-optimal neurohormonal blockade/modulation, addressing hyperkalemia is an important issue when treating HFrEF patients.

Sacubitril/valsartan in everyday clinical practice: an observational study based on the experience of a heart failure clinic.

BACKGROUND: Heart failure (HF) is a growing public health problem. Sacubitril/valsartan is now recommended to be used in persistently symptomatic patients with left ventricular ejection fraction (LVEF) <40%, replacing angiotensin-converting enzyme inhibitors (ACEis)/angiotensin receptor blockers (ARBs). In the present study, we aimed to characterise the challenges of sacubitril/valsartan use in everyday clinical practice. METHODS: We assessed the medical records of patients with HF and reduced ejection fraction eligible for sacubitril/valsartan attending a HF clinic at a Portuguese University Hospital during 2018 (n=152). The number of eligible patients receiving the drug and the reasons for not prescribing sacubitril/valsartan were evaluated. Additionally, we assessed the tolerability of maximal doses of sacubitril/valsartan. New York Heart Association functional class (NYHA class) and LVEF before and after up-titration to maximal tolerated sacubitril/valsartan dose were compared. Median follow-up was 41 months. RESULTS: Of the 152 included patients, 75 (49%) were prescribed the drug. The two main reasons for non-prescription were patient financial barriers (31%) and hypotension (27%). Only 33% of patients on sacubitril/valsartan did reach maximal dose. Hypotension was the main limiting factor for dose optimisation. Duration of sacubitril/valsartan treatment showed a positive association with LVEF improvement during follow-up (6.6% absolute LVEF increase/year). NYHA functional class improved significantly from baseline through the end of follow-up. CONCLUSIONS: In every-day clinical practice, although sacubitril/valsartan was associated with a marked improvement in NYHA class and in LVEF, important financial and clinical barriers to the implementation of this therapy were identified.

Periatrial Fat Quality Predicts Atrial Fibrillation Ablation Outcome.

Background Previous studies showed that the quantity of the left atrial (LA) periatrial fat tissue predicts recurrence after catheter ablation of atrial fibrillation (AF). We hypothesized that the quality of the LA periatrial fat tissue, measured by the mean computed tomography attenuation, predicts recurrence after AF ablation independent of the quantity of the LA periatrial fat tissue. Methods We included 143 consecutive patients with drug-refractory AF referred for the first catheter ablation of AF (62.2±10 years, 40% nonparoxysmal AF). All participants had a preablation cardiac computed tomography. We measured the quantity of the LA periatrial fat tissue by the area (millimeter square) and the quality by the mean computed tomography attenuation (Hounsfield units) in a standard 4-chamber view. Results Patients with AF recurrence after ablation (n=57) had a significantly larger fat area (167.6 [interquartile range, 124.1-255] versus 145.4 [95.6-229.3] mm2; P=0.018) and a higher fat attenuation (-92.0±9.8 versus -96.5±9.4 Hounsfield units; P=0.006) than those without recurrence (controls). LA fat attenuation was correlated with LA fat volume and LA bipolar voltage by invasive mapping and was associated with AF recurrence after adjusting for clinical risk factors, including body mass index, AF type, LA dimension, and fat area (hazard ratio, 2.65; P=0.001). Conclusions The quality of the LA periatrial fat tissue is an independent predictor of recurrence after the first AF ablation. Assessment of LA periatrial fat attenuation can improve AF ablation outcomes by refining patient selection.

How is Bariatric Surgery Improving the Quality of Life of Obese Patients: A Portuguese Cross-Sectional Study.

INTRODUCTION: Obesity is often accompanied by psychological distress and both can reduce patients' quality of life. Bariatric surgery is proven to be a good method to reduce weight and to alleviate comorbidities, leading ultimately to an improvement in quality of life. MATERIAL AND METHODS: The authors studied 80 patients enrolled in the Multidisciplinary Bariatric Unit of a central hospital in Porto, Portugal. Patients submitted to Roux-en-Y gastric bypass and sleeve procedures were compared. Laboratory parameters were collected from patients' files. Quality of life and psychological state - depression and anxiety, were evaluated using the Portuguese versions of the Medical Outcomes Study SF-36 and the hospital anxiety and depression scale, respectively, within one to two years of the surgery. RESULTS: A total of 51 patients were operated and completed a quality of life evaluation, while 21 patients were in a pre-operatory group (control). Patients subjected to bariatric surgery had higher scores of SF-36 and lower scores in both hospital anxiety and depression scale (anxiety and depression) subscales (p < 0.001); SF-36 presented a Pearson correlation coefficient of 0,475 (p = 0.004) with hemoglobin A1c. Sleeve had better results in the hospital anxiety and depression scale-depression subscale (p = 0.073). DISCUSSION: In this population, bariatric surgery led to better results, regarding both metabolic and psychological evaluations. No significant differences were found between gastric bypass and sleeve. However, further analyses must be performed. CONCLUSION: This study supports the theory that bariatric surgery contributes to the improvement of obese patients' quality of life and psychological state.

Introdução: A obesidade é frequentemente acompanhada por perturbações psicológicas, e ambos podem reduzir a qualidade de vida dos doentes. Está provado que a cirurgia bariátrica é um bom método de redução de peso e para aliviar comorbilidades, conduzindo em última instância a uma melhoria da qualidade de vida. Material e Métodos: Os autores estudaram 80 doentes seguidos em consulta do Centro Multidisciplinar de Tratamento da Obesidade. Os grupos de bypass gástrico em Y-de-Roux e sleeve gástricos foram comparados. Os parâmetros analíticos foram recolhidos dos processos dos doentes. A qualidade de vida e perturbações psicológicas (depressão e ansiedade) foram avaliadas um a dois anos após a cirurgia usando as versões portuguesa do Medical Outcomes Study SF-36 e da escala de depressão e ansiedade hospitalar. Resultados: Um total de 51 doentes foi operado, tendo completado uma avaliação de qualidade de vida, enquanto 21 estavam num grupo pré-operatório (controlo). Doentes submetidos a cirurgia bariátrica tiveram resultados mais elevados no SF-36 e valores menores em ambas as subescalas (ansiedade e depressão) da escala de depressão e ansiedade hospitalar (p < 0,001). O SF-36 apresentou um coeficiente de correlação de Pearson de 0,475 (p = 0,004) com a hemoglobina A1c. O sleeve teve melhores resultados na subescala escala de depressão e ansiedade hospitalar-depressão (p = 0,073). Discussão: Nesta população, a cirurgia bariátrica conduziu a melhores resultados nas avaliações metabólica e psicológica, não tendo sido encontradas diferenças significativas entre bypass e sleeve. Contudo, uma análise posterior deverá ser realizada. Conclusão: Este estudo corrobora a teoria de que a cirurgia bariátrica contribui para a melhoria da qualidade de vida e do estado psicológico dos doentes obesos.

Consenso sobre Ecocardiografia transesofágica perioperatória da Sociedade Brasileira de Anestiologia e do Departamento de Imagem Cardiovascular da Sociedade Brasileira de Cardiologia / Consensus on perioperative transesophageal echocardiography of the Brazilian Society of Anesthesiology and the Department of Cardiovascular Image of the Brazilian Society of Cardiology

A Sociedade Brasileira de Anestesiologia, pelo Núcleo Vida de Ecocardiografia Transesofágica Intraoperatória (ETTI/SBA) juntamente com o Departamento de Imagem Cardiovascular da Sociedade Brasileira de Cardiologia (DIC/SBC), fez uma força-tarefa para normatizar a feitura da ecocardiografia transesofágica intraoperatória para os anestesiologistas e ecocardiografistas brasileiros com base nas evidências científicas da Sociedade dos Anestesiologistas Cardiovasculares/Sociedade Americana de Ecocardiografia (SCA/ASE) e da Sociedade Brasileira de Cardiologia

Consenso sobre Ecocardiografia Transesofágica Perioperatória da Sociedade Brasileira de Anestesiologia e do Departamento de Imagem Cardiovascular da Sociedade Brasileira de Cardiologia / Consensus on Perioperative Transesophageal Echocardiography of the BrazilianSociety of Anesthesiology and the Department of Cardiovascular Image of theBrazilian Society of Cardiology

RESUMO A Sociedade Brasileira de Anestesiologia, pelo Núcleo Vida de Ecocardiografia Transe-sofágica Intraoperatória (ETTI/SBA) juntamente com o Departamento de Imagem Cardiovascularda Sociedade Brasileira de Cardiologia (DIC/SBC), fez uma forc ̧a-tarefa para normatizar afeitura da ecocardiografia transesofágica intraoperatória para os anestesiologistas e ecocar-diografistas brasileiros com base nas evidências científicas da Sociedade dos AnestesiologistasCardiovasculares/Sociedade Americana de Ecocardiografia (SCA/ASE) e da Sociedade Brasileirade Cardiologia.

ABSTRACT Through the Life Cycle of Intraoperative Transesophageal Echocardiography(ETTI/SBA) the Brazilian Society of Anesthesiology, together with the Department of Cardi-ovascular Image of the Brazilian Society of Cardiology (DIC/SBC), createded a task force tostandardize the use of intraoperative transesophageal echocardiography by Brazilian anesthesi-ologists and echocardiographers based on scientific evidence from the Society of CardiovascularAnesthesiologists/American Society of Echocardiography (SCA/ASE) and the Brazilian Society ofCardiology.

Consenso sobre Ecocardiografia Transesofágica Perioperatória da Sociedade Brasileira de Anestesiologia e do Departamento de Imagem Cardiovascular da Sociedade Brasileira de Cardiologia / Consensus on Perioperative Transesophageal Echocardiography of the BrazilianSociety of Anesthesiology and the Department of Cardiovascular Image of theBrazilian Society of Cardiology

RESUMO: A Sociedade Brasileira de Anestesiologia, pelo Núcleo Vida de Ecocardiografia Transesofágica Intraoperatória (ETTI/SBA) juntamente com o Departamento de Imagem Cardiovascular da Sociedade Brasileira de Cardiologia (DIC/SBC), fez uma força-tarefa para normatizar a feitura da ecocardiografia transesofágica intraoperatória para os anestesiologistas e ecocardiografistas brasileiros com base nas evidências científicas da Sociedade dos Anestesiologistas Cardiovasculares/Sociedade Americana de Ecocardiografia (SCA/ASE) e da Sociedade Brasileira de Cardiologia.

ABSTRACT: Through the Life Cycle of Intraoperative Transesophageal Echocardiography (ETTI/SBA) the Brazilian Society of Anesthesiology, together with the Department of Cardiovascular Image of the Brazilian Society of Cardiology (DIC/SBC), createded a task force to standardize the use of intraoperative transesophageal echocardiography by Brazilian anesthesiologists and echocardiographers based on scientific evidence from the Society of Cardiovascular Anesthesiologists/American Society of Echocardiography (SCA/ASE) and the Brazilian Society of Cardiology.

[Consensus on Perioperative Transesophageal Echocardiography of the Brazilian Society of Anesthesiology and the Department of Cardiovascular Image of the Brazilian Society of Cardiology]. / Consenso sobre Ecocardiografia Transesofágica Perioperatória da Sociedade Brasileira de Anestesiologia e do Departamento de Imagem Cardiovascular da Sociedade Brasileira de Cardiologia.

Through the Life Cycle of Intraoperative Transesophageal Echocardiography (ETTI/SBA) the Brazilian Society of Anesthesiology, together with the Department of Cardiovascular Image of the Brazilian Society of Cardiology (DIC/SBC), createded a task force to standardize the use of intraoperative transesophageal echocardiography by Brazilian anesthesiologists and echocardiographers based on scientific evidence from the Society of Cardiovascular Anesthesiologists/American Society of Echocardiography (SCA/ASE) and the Brazilian Society of Cardiology.

Disfunçäo temporomandibular: aspéctos anátomo-semiológicos / Dysfunction temporomandibular: anatomo-semiologic aspects

Este trabalho tem como objetivo rever alguns aspéctos anátomo-semiológicos da Disfunçäo Temporomandibular. A Articulaçäo Temporomandibular é uma juntura de fisiologia complexa. Portanto, a manutençäo de um equilíbrio funcional desta juntura com as demais estruturas da cabeça e do pescoço é necessária para que este equilíbrio näo se rompa vindo a causar danos à articulaçäo e ou as demais estruturas craniomandibulares. É sugerida uma rotina de exame através do qual o Fisiatra possa diagnosticar e orientar a recuperaçäo funcional de uma Disfunçäo Temporomandibular, principalmente, de causa muscular